Portfolio breakdown

POSITIONS
Ionis Pharmaceuticals
14.60%
Argenx SE
14.10%
Revolution Medicines
9.30%
Neurocrine Biosciences
8.80%
Alnylam Pharmaceuticals
7.10%
Vertex Pharmaceuticals
6.40%
Agios Pharmaceuticals
5.30%
Incyte
4.40%
Scholar Rock
4.30%
Akero Therapeutics
4.00%
Immunocore
3.60%
Avidity Biosciences
3.40%
Celldex Therapeutics
3.30%
Beam Therapeutics
2.50%
Rivus Pharmaceuticals
1.90%
Edgewise Therapeutics
1.60%
Relay Therapeutics
1.60%
Biohaven
1.50%
Wave Life Sciences
1.10%
Annexon
0.60%
Macrogenics
0.60%
Financial Health
Profitable
Financed to break even / product at market
Pipeline companies / additional financing required (> 2 years)
Pipeline companies / acute financing required (<2 years)
Disease area
Orphan Diseases
Inflammation & Immunology
Oncology
Neurological Diseses
Cardiovascular Diseases
market capitalization (in usd)
> 30 bn
Private
5 - 30 bn
500 mn - 1 bn
1 - 5 bn
< 500 mn
Technology
Small Molecule
Antibody
RNA
Gene- and cell therapy

Facts & key figures

Investment Focus

Innovative biotechnology companies developing differentiated therapies

Primarily invested in listed biotechnology companies, with selective private investments

20–35 target participations

5–8 core positions with meaningful portfolio weights

suitability & risk profile
Designed for long-term investors (5+ years) willing to accept equity risk typical of the biotech sector.
Lower Risk
Higher Risk
Risk metrics (3Y)
NBI (Nasday Biotechnology Index) is used as the benchmark and the reference currency is CHF.
general information

Benefits & risks

Access to global biotech growth

Diversified portfolio of profitable and pipeline companies

Experienced investment management

Dividend policy (~5%)

Equity volatility

Biotech sector swings

Currency risks

Discount/premium to NAV

Up to 15% leverage possible

Downloads